Sutro Biopharma Announces Oral Presentation at the 64th American Society of Hematology Annual Meeting and Exposition

On November 3, 2022 Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), reported that data from the Company’s compassionate use program on anti-leukemic activity of STRO-002, a novel folate receptor-α (FR-α) targeting ADC, in infants and children with relapsed/refractory CBF2AT3-GLIS2 acute myeloid leukemia (AML) will be reviewed in an oral presentation at the 64th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition (ASH) (Free ASH Whitepaper) (Press release, Sutro Biopharma, NOV 3, 2022, View Source [SID1234622909]). The meeting will take place December 10 – 13, 2022 in New Orleans, LA.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Soheil Meshinchi, M.D., Ph.D., Principal Investigator for the compassionate use program with STRO-002 in relapsed/refractory CBF2AT3-GLIS2 AML, will deliver the oral presentation at 10:45 a.m. CST on December 10, 2022. Dr. Meshinchi is Professor, Clinical Research Division, at Fred Hutchinson Cancer Research Center and Professor, Division of Pediatric Hematology-Oncology, at the University of Washington School of Medicine.

"As a patient-driven company, we at Sutro are extremely pleased that STRO-002— which we are presently developing in ovarian cancer—had a profound effect in a pediatric patient group with a rare form of AML, for which treatment options are limited," said Bill Newell, Sutro’s Chief Executive Officer. "Among the highlights from our compassionate use program, there were a number of complete responses, which is particularly encouraging considering these patients are typically refractory to standard-of-care. We look forward to an oral presentation of the full data set at ASH (Free ASH Whitepaper) in December."

Oral Presentation Details:

Abstract Title: Anti-Leukemic Activity of STRO-002 a Novel Folate Receptor-α (FR-α)-Targeting ADC in Relapsed/Refractory CBF2AT3-GLIS2 AML
Session: Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Relapsed/Refractory AMLS Session
Date: Saturday, December 10, 2022
Session Time: 9:30 a.m. – 11:00 a.m. CST
Presentation Time: 10:45 a.m. CST

The accepted ASH (Free ASH Whitepaper) abstract will be made available today on the congress platform here, and a whitepaper with details about this rare indication and Sutro’s compassionate use program is now available on the Company’s website here. Following the conference, the presentation materials will be available in the "Clinical/Scientific Presentation and Publication Highlights" section of Sutro Biopharma’s website at www.sutrobio.com.